{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:34:58Z","timestamp":1792870498250,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["1R01CA249666-01A1"],"award-info":[{"award-number":["1R01CA249666-01A1"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ctrv.2022.102378","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T20:44:57Z","timestamp":1647031497000},"page":"102378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":190,"special_numbering":"C","title":["Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\/pneumonitis\u2014Focus on proactive monitoring, diagnosis, and management"],"prefix":"10.1016","volume":"106","author":[{"given":"Sandra M.","family":"Swain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Bartholmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schumacher-Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ctrv.2022.102378_b0005","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102378_b0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102378_b0015","doi-asserted-by":"crossref","first-page":"e112136","DOI":"10.1371\/journal.pone.0112136","article-title":"Increased expression of cathepsin L: A novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients","volume":"9","author":"Ruan","year":"2014","journal-title":"PLoS One"},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2022.102378_b0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/prca.201300105","article-title":"Cathepsin B: Multiple roles in cancer","volume":"8","author":"Aggarwal","year":"2014","journal-title":"Proteomics Clin Appl"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102378_b0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102378_b0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102378_b0035","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im S, Park YH, Hegg R, et al. Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) in patients With HER2+ metastatic breast cancer: Results of the randomized, phase 3 study DESTINY breast03. presented at: ESMO congress; September 16-21, 2021.","DOI":"10.1016\/j.annonc.2021.08.2087"},{"issue":"25","key":"10.1016\/j.ctrv.2022.102378_b0040","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102378_b0045","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Presented at: ESMO Congress; September 16-21, 2021.","DOI":"10.1016\/j.annonc.2021.08.2135"},{"key":"10.1016\/j.ctrv.2022.102378_b0050","unstructured":"Enhertu (trastuzumab deruxtecan). Summary of product characteristics. Daiichi Sankyo Europe GmbH; 2021."},{"key":"10.1016\/j.ctrv.2022.102378_b0055","unstructured":"Enhertu (trastuzumab deruxtecan). Summary of product characteristics. Daiichi Sankyo Company, Limited; 2020."},{"key":"10.1016\/j.ctrv.2022.102378_b0060","unstructured":"Enhertu (fam-trastuzumab deruxtecan-nxki). Prescribing information. Daiichi Sankyo, Inc.; 2021."},{"key":"10.1016\/j.ctrv.2022.102378_b0065","unstructured":"Enhertu (trastuzumab deruxtecan). Product monograph. Daiichi Sankyo Company, AstraZeneca Canada Inc; 2021."},{"key":"10.1016\/j.ctrv.2022.102378_b0070","unstructured":"ClinicalTrials.gov. A phase 2 study of T-DXd in patients with selected HER2 expressing tumors (DPT02). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04482309 (accessed May 25 2021)."},{"key":"10.1016\/j.ctrv.2022.102378_b0075","unstructured":"ClinicalTrials.gov. A Study of T-DXd for the treatment of solid tumors harboring HER2 activating mutations (DPT01). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639219 (accessed May 19 2021)."},{"key":"10.1016\/j.ctrv.2022.102378_b0080","unstructured":"ClinicalTrials.gov. Trastuzumab deruxtecan in participants with HER2-overexpressing advanced or metastatic colorectal cancer (DESTINY-CRC02). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04744831 (accessed May 19 2021)."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102378_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9504","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01","volume":"38","author":"Smit","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102378_b0090","unstructured":"ClinicalTrials.gov. Trastuzumab deruxtecan (DS-8201a) versus investigator's choice for HER2-low breast cancer that has spread or cannot be surgically removed [DESTINY-Breast04]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03734029 (accessed May 19 2021)."},{"key":"10.1016\/j.ctrv.2022.102378_b0095","unstructured":"ClinicalTrials.gov. Study of trastuzumab deruxtecan (T-DXd) vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer (DB-06). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04494425 (accessed May 19 2021)."},{"key":"10.1016\/j.ctrv.2022.102378_b0100","unstructured":"ClinicalTrials.gov. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04784715 (accessed June 3 2021)."},{"key":"10.1016\/j.ctrv.2022.102378_b0105","unstructured":"ClinicalTrials.gov. Ph1b\/2 study of the safety and efficacy of T-DXd combinations in advanced HER2+ gastric cancer (DESTINY-Gastric03) (DG-03). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04379596 (accessed June 10 2021)."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102378_b0110","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102378_b0115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: A systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102378_b0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.37549\/AR2270","article-title":"Deciphering drug-induced interstitial lung disease: A mechanistic approach","volume":"45","author":"Ripley","year":"2016","journal-title":"Applied Radiology"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102378_b0125","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102378_b0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2022.102378_b0135","article-title":"Interstitial Lung Disease","author":"Antoine","year":"2021","journal-title":"StatPearls Treasure Island (FL): StatPearls Publishing LLC"},{"key":"10.1016\/j.ctrv.2022.102378_b0140","doi-asserted-by":"crossref","unstructured":"Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med 2014;2:4.","DOI":"10.1186\/2213-0802-2-4"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102378_b0145","doi-asserted-by":"crossref","first-page":"967","DOI":"10.7150\/ijms.32752","article-title":"Management of chronic respiratory failure in interstitial lung diseases: Overview and clinical insights","volume":"16","author":"Faverio","year":"2019","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102378_b0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: Mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102378_b0155","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102378_b0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102378_b0165","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","article-title":"Interstitial lung disease as an adverse drug reaction in Japan: Exploration of regulatory actions as a basis for high reporting","volume":"43","author":"Iwasa","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2022.102378_b0170","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0, 2017."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102378_b0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","article-title":"Radiation-induced lung injury: Current evidence","volume":"21","author":"Arroyo-Hern\u00e1ndez","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102378_b0180","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1513\/pats.201112-055AW","article-title":"The genetic and environmental causes of pulmonary fibrosis","volume":"9","author":"Macneal","year":"2012","journal-title":"Proc Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102378_b0185","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.chest.2017.03.033","article-title":"The role of infection in interstitial lung diseases: A review","volume":"152","author":"Azadeh","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102378_b0190","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102378_b0195","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102378_b0200","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102378_b0205","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2022.102378_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102378_b0215","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2022.102378_b0220","doi-asserted-by":"crossref","unstructured":"Janne PA, Baik CS, Su W-C, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFRmutated (EGFRm) non-small cell lung cancer (NSCLC). Wolters Kluwer Health 2021;39(15_suppl).","DOI":"10.1200\/JCO.2021.39.15_suppl.9007"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102378_b0225","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jtho.2021.01.280","article-title":"03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study","volume":"16","author":"Spira","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102378_b0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3892\/mco.2016.1113","article-title":"Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases","volume":"6","author":"Sugaya","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102378_b0235","unstructured":"KADCYLA\u00ae (ado-trastuzumab emtansine). Prescribing information. Genentech, Inc.; 2020."},{"issue":"8","key":"10.1016\/j.ctrv.2022.102378_b0240","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102378_b0245","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Park H, Frentzas S, Shannon CM, Cuff K, Eek RW, et al. Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-over-expressing solid tumors: Results from two phase 1 clinical trials. J Clin Oncol 2021;39(15_suppl): Abstract 1038.","DOI":"10.1200\/JCO.2021.39.15_suppl.1038"},{"key":"10.1016\/j.ctrv.2022.102378_b0250","doi-asserted-by":"crossref","unstructured":"Manich CS, O\u2019Shaughnessy J, Aftimos PG, van den Tweel E, Oesterholt M, Escriv\u00e1-de-Roman\u00ed SI, et al. Primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol 2021;32:S1283\u2013346.","DOI":"10.1016\/j.annonc.2021.08.2088"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102378_b0255","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102378_b0260","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102378_b0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: A single-institution retrospective study","volume":"10","author":"Okada","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102378_b0270","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102378_b0275","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: A multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2022.102378_b0280","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.12.016","article-title":"Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer","volume":"104","author":"Kato","year":"2017","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102378_b0285","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2022.102378_b0290","doi-asserted-by":"crossref","unstructured":"Galsky M, Del Conte G, Foti S, Yu EY, Machiels J-PH, Doger B, et al. Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J Clin Oncol 2022;40. Abstract 438.","DOI":"10.1200\/JCO.2022.40.6_suppl.438"},{"key":"10.1016\/j.ctrv.2022.102378_b0295","unstructured":"ClinicalTrials.gov. DS8201a and pembrolizumab in participants with locally advanced\/metastatic breast or non-small cell lung cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04042701 (accessed February 17 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0300","unstructured":"ClinicalTrials.gov. A phase 1b\/2 study of T-DXd combinations in HER2-positive metastatic breast cancer (DB-07). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04538742 (accessed February 17 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0305","unstructured":"ClinicalTrials.gov. A phase 1b study of T-DXd combinations in HER2-low advanced or metastatic breast cancer (DB-08). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04556773 (accessed February 17 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0310","unstructured":"ClinicalTrials.gov. A study of novel anti-cancer agents in patients with metastatic triple negative breast cancer (BEGONIA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03742102 (accessed February 17 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0315","unstructured":"ClinicalTrials.gov. Phase Ib study of the safety of T-DXd and durvalumab with chemotherapy in advanced or metastatic HER2+ non-squamous NSCLC (DL03). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04686305 (accessed February 17 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0320","unstructured":"ClinicalTrials.gov. Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1\/PD-L1 containing therapy (HUDSON). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03334617 (accessed February 17 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0325","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. NDA\/BLA multi-disciplinary review and evaluation {BLA 761139} ENHERTU (fam-trastuzumab deruxtecan-nxki) 2019."},{"key":"10.1016\/j.ctrv.2022.102378_b0330","doi-asserted-by":"crossref","unstructured":"Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease in 8 single-arm trastuzumab deruxtecan studies. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; Virtual. [abstract CT167].","DOI":"10.1158\/1538-7445.AM2021-CT167"},{"key":"10.1016\/j.ctrv.2022.102378_b0335","doi-asserted-by":"crossref","unstructured":"Powell CA, Modi S, Iwata H, Takahashi S, Nie K, Qin A, et al. Analysis of study drug-related interstitial lung disease in patients with HER2+ metastatic breast cancer treated with trastuzumab deruxtecan. Presented at: ESMO Breast Cancer Virtual Congress; May 5-8, 2021.","DOI":"10.1016\/j.annonc.2021.03.106"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102378_b0340","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102378_b0345","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2022.102378_b0350","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2022.102378_b0355","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.04.015","article-title":"The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis","volume":"132","author":"Suh","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102378_b0360","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.2096","article-title":"Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors","volume":"109","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102378_b0365","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/annrheumdis-2018-214263","article-title":"Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"78","author":"Namba","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102378_b0370","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yexmp.2009.07.008","article-title":"Non-invasive diagnosis of early pulmonary disease in PECAM-deficient mice using infrared pulse oximetry","volume":"87","author":"Early","year":"2009","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102378_b0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0970-2113.80340","article-title":"The uses of overnight pulse oximetry","volume":"37","author":"Singh","year":"2020","journal-title":"Lung India"},{"key":"10.1016\/j.ctrv.2022.102378_b0380","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02494-2016","article-title":"Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease","volume":"49","author":"Schaeffer","year":"2017","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102378_b0385","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/resp.13226","article-title":"Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD","volume":"23","author":"Du Plessis","year":"2018","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102378_b0390","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","article-title":"A multidisciplinary toxicity team for cancer immunotherapy-related adverse events","volume":"17","author":"Naidoo","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102378_b0395","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102378_b0400","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1007\/s00330-020-06986-4","article-title":"Deep learning in interstitial lung disease-how long until daily practice","volume":"30","author":"Trusculescu","year":"2020","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102378_b0405","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/cancers13051052","article-title":"Drug-related pneumonitis in cancer treatment during the COVID-19 era","volume":"13","author":"Cherri","year":"2021","journal-title":"Cancers"},{"issue":"42","key":"10.1016\/j.ctrv.2022.102378_b0410","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.3748\/wjg.v11.i42.6607","article-title":"Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma","volume":"11","author":"Gad","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102378_b0415","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102378_b0420","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102378_b0425","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102378_b0430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/CAD.0b013e3283473f28","article-title":"Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports","volume":"22","author":"Yoshii","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102378_b0435","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.21873\/anticanres.12939","article-title":"Preexisting interstitial lung disease and lung injury associated with irinotecan in patients with neoplasms","volume":"38","author":"Ozawa","year":"2018","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102378_b0440","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00280-015-2816-6","article-title":"Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease","volume":"76","author":"Enomoto","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102378_b0445","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/RLI.0000000000000574","article-title":"Computer-aided diagnosis of pulmonary fibrosis using deep learning and CT images","volume":"54","author":"Christe","year":"2019","journal-title":"Invest Radiol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102378_b0450","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/jcm8101698","article-title":"Exploring the ability of electronic nose technology to recognize interstitial lung diseases (ILD) by non-invasive breath screening of exhaled volatile compounds (VOC): A pilot study from the european IPF registry (eurIPFreg) and biobank","volume":"8","author":"Krauss","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2022.102378_b0455","unstructured":"Interstitial Lung Disease. ATS clinical practice guidelines & statements. https:\/\/www.thoracic.org\/education-center\/ild\/resources.html (accessed February 22 2022)."},{"key":"10.1016\/j.ctrv.2022.102378_b0460","doi-asserted-by":"crossref","unstructured":"Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 2021;S485\u20136.","DOI":"10.1016\/j.annonc.2021.08.562"},{"key":"10.1016\/j.ctrv.2022.102378_b0465","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jtho.2021.01.285","article-title":"Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: Interim results of DESTINY-Lung01","volume":"2021","author":"Nakagawa","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:20:38Z","timestamp":1778685638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":93,"alternative-id":["S0305737222000421"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\/pneumonitis\u2014Focus on proactive monitoring, diagnosis, and management","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102378"}}